Liver Fibrosis: A New Frontier in Drug Discovery
Liver fibrosis is a scarring process that can lead to liver cirrhosis, which causes more than 1.4 million deaths each year. Stanford University School of Medicine geneticist Gary Peltz is using Co-Scientist to speed the search for drugs that can slow, stop or reverse genesis.
Exploring Innovative Drug Identification Methods
In a study published in Advanced Science, Peltz’s team examined whether Co-Scientist could support efforts to identify drugs from the extensive literature of existing drugs that could be used to treat fibrosis. Peltz asked the co-scientist to suggest three candidates and explain their rationale. He also self-identified two candidate drugs based on their notable presence in the liver fibrosis literature.
Rigorous Testing Yields Promising Results
Peltz then subjected all five drugs to his lab’s fibrosis test rig, which consists of living human liver cells. His two medication recommendations showed no benefit against fibrosis. In contrast, two of the three drug candidates selected by the co-scientist blocked fibrosis and promoted liver cell regeneration. One of these drugs has only been linked to liver fibrosis in a few publications – a needle in a haystack of scientific literature.
A Breakthrough with Cancer Drug Vorinostat
The co-scientist’s standout choice was the cancer drug vorinostat. In Peltz’s experiments, it blocked 91% of a damaging reaction that can lead to liver scarring. The co-scientist’s suggestions pointed to drugs that remodel gene activity rather than targeting a single fibrosis pathway. Peltz argues that such drugs deserve serious consideration for treating liver fibrosis and could ultimately help bring a new generation of antifibrotic drugs to market.
By leveraging advanced AI in drug discovery, this research underscores the potential to uncover hidden gems in medical literature that could significantly impact patient outcomes. For more information, visit the source link Here.
“`
